Opus Genetics (IRD) Proxy filing summary

Executive summary

• Annual meeting scheduled for April 20, 2026, via virtual webcast; record date is March 5, 2026.

• Stockholders will vote on four key proposals: election of nine directors, ratification of Ernst & Young as auditor, advisory approval of executive compensation, and amendment to increase authorized common stock.

• Board recommends voting in favor of all proposals; proxy materials and voting instructions provided.

• Board and management engaged with major investors representing 53% of outstanding shares in 2025.

Voting matters and shareholder proposals

• Proposal 1: Elect nine director nominees for one-year terms.

• Proposal 2: Ratify Ernst & Young, LLP as independent auditor for fiscal year ending December 31, 2026.

• Proposal 3: Advisory vote to approve executive compensation (say-on-pay).

• Proposal 4: Approve amendment to increase authorized common stock from 125 million to 250 million shares.

• Board recommends voting “FOR” all proposals.

Board of directors and corporate governance

• Board consists of nine directors with diverse expertise in biotech, ophthalmology, finance, and corporate development.

• Independent Chair and CEO roles are separated; majority of directors are independent.

• Fully independent Audit, Compensation, and Nominating & Corporate Governance Committees.

• Annual board and committee self-evaluations; proactive stockholder engagement.

• Stockholders elect all directors annually and may remove directors by majority vote.